Abstract
Didemnin B is a member of a class of compounds, derived from a marine source, undergoing phase II study. Twenty-two patients with relapsed myeloma were treated with didemnin B at an initial dose of 4.9 mg/m2, given once every 28 days. All were evaluable for toxicity, and 15 were evaluable for myeloma response. No tumor regressions occurred in the 15 patients evaluable for response. Vomiting was the major toxicity, occurring in 73% of patients despite vigorous pre- and post-treatment medication with at least three intravenous antiemetics. Two instances of grade 4 hypersensitivity reaction occurred. We conclude that didemnin B has no activity at this dose and schedule in myeloma that has relapsed after one or two prior therapeutic regimens.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Kyle RA: Multiple myeloma. An update on diagnosis and management. Acta Oncol 29:1–8, 1990
Buzaid AC, Durie BGM: Management of refractory myeloma: A review. J Clin Oncol 6:889–905, 1988
Rinehart KL, Kishore V, Bible KC, Sakai R, Sullins DW, Li K-M: Didemnins and tunichlorin: Novel natural products from the marine tunicateTrididemnun solidum. J Natural Prod 51:1–21, 1988
Chun HG, Davies B, Hoth D, Suffness M, Plowman J, Flora K, Grieshaber C, Leyland-Jones B: Didemnin B: The first marine compound entering clinical trials as an antineoplastic agent. Invest New Drugs 4:279–284, 1986
Dorr FA, Kuhn JG, Phillips J, Von Hoff DD: Phase I clinical and pharmacokinetic investigation of didemnin B, a cyclic depsipeptide. Eur J Cancer Clin Oncol 24: 1699–1706, 1988
Shin DM, Holoye PY, Murphy WK, Forman A, Papasozomenos SC, Hong WK, Raber M: Phase I/II clinical trial of didemnin B in non-small-cell lung cancer: Neuromuscular toxicity is dose-limiting. Cancer Chemother Pharmacol 29:145–149, 1991
Jones DV, Ajani JA, Blackburn R, Daugherty K, Levin B, Patt YZ, Abbruzzese JL: Phase II study of didemnin B in advanced colorectal cancer. Invest New Drugs 10:211–213, 1992
Malfetano JH, Blessing JA, Jacobs AJ: A phase II trial of didemnin B (NSC #335319) in patients with previously treated epithelial ovarian cancer. A Gynecologic Oncology Group study. Am J Clin Oncol (CCT) 16:47–49, 1993
Weiss RB, Donehower RC, Wiernik PH, Ohnuma T, Gralla RJ, Trump DL, Baker JR, Van Echo DA, Von Hoff DD, Leyland-Jones B: Hypersensitivity reactions from taxol. J Clin Oncol 8:1263–1268, 1990
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Weiss, R.B., Peterson, B.L., Allen, S.L. et al. A phase II trial of didemnin B in myeloma. Invest New Drugs 12, 41–43 (1994). https://doi.org/10.1007/BF00873234
Issue Date:
DOI: https://doi.org/10.1007/BF00873234